Homoharringtonine binds to and increases myosin‐9 in myeloid leukaemia
Authors:
Open Access
- 8 October 2015
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 173 (1) , 212-221
Abstract
Background and Purpose: Homoharringtonine (HHT) is a natural alkaloid isolated from various Cephalotaxus species. HHT has been used to treat acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), chronic lymphocyte leukaemia and myelodysplastic syndromes. Although HHT inhibits protein synthesis and promotes apoptosis of leukaemia cells in preclinical studies, its molecular target proteins remain unknown. The aim of this study was to identify target proteins of HHT.Experimental Approach: We have synthesized a biotinylated affinity column and used it to identify targets of HHT and confirmed the results by MS and Western blots. We also examined the effects of HHT on the target protein and determined roles of the target protein in anti‐leukaemia activities of HHT through Western blots, flow cytometry and retrovirus transfection.Key Results: Myosin‐9, a member of the myosin super‐family, was identified as a direct interactor of HHT. Furthermore, HHT up‐regulated the expression level of myosin‐9 in both AML and CML cell lines in a time‐dependent manner. Thus, HHT‐induced apoptosis of leukaemia cells begins in 6 h and continues to increase for 24 h. There is a positive correlation between up‐regulated myosin‐9 expression level and increased percentage of apoptotic cells mediated by HHT. Overexpression of myosin‐9 could increase the sensitivity of the leukaemia cells to the cytotoxicity of HHT and arrest cells in S and G2/M phases.Conclusions and Implications: Our results indicated that myosin‐9 was the target protein of HHT and played an important role in the HHT‐induced apoptosis of leukaemia cells.Keywords
Funding Information
- National Natural Science Foundation of China (81370643‐H0812)
This publication has 34 references indexed in Scilit:
- Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trialThe Lancet Oncology, 2013
- Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemiaBlood, 2011
- Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1Nature, 2010
- Non-muscle myosin II takes centre stage in cell adhesion and migrationNature Reviews Molecular Cell Biology, 2009
- U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:Journal of Molecular Biology, 2009
- Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapyCancer, 2007
- A Sequential Blockade Strategy for the Design of Combination Therapies to Overcome Oncogene Addiction in Chronic Myelogenous LeukemiaCancer Research, 2006
- Myosin domain evolution and the primary divergence of eukaryotesNature, 2005
- In vitro effects of STI 571‐containing drug combinations on the growth of Philadelphia‐positive chronic myelogenous leukemia cellsCancer, 2002
- Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formationFEBS Letters, 1989